

# Survival Rates For Feline Infectious Peritonitis With Antiviral Therapy

## SURVIVAL RATES FOR FELINE INFECTIOUS PERITONITIS WITH ANTIVIRAL THERAPY

Imogen Franklin<sup>1</sup>, Sally Coggins<sup>1,2</sup>, Samantha Taylor<sup>3,4</sup>, Kamalan Jeevaratnam<sup>4</sup>, Jodie Green<sup>5</sup>, Krystle Reagan<sup>6</sup>, Mary Thompson<sup>1</sup>

<sup>1</sup>*Sydney School of Veterinary Science, The University of Sydney, Australia*

<sup>2</sup>*Centre for Veterinary Education, The University of Sydney, Australia*

<sup>3</sup>*International Society of Feline Medicine, Tisbury, UK*

<sup>4</sup>*University of Surrey, Guildford, UK*

<sup>5</sup>*Royal Veterinary College, Hatfield, UK*

<sup>6</sup>*Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA, USA*

Recent availability of antiviral drugs remdesivir and GS-441524 has made Feline Infectious Peritonitis (FIP) treatable.<sup>(1-3)</sup> This study determines treatment phase-specific survival rates in cats as they undergo treatment, for the purpose of prognostication for owners.

A secondary analysis of mortality data from four published studies (n=385) was conducted with permission. All cats received  $\geq 84$  days of remdesivir, GS-441524, or both (5-30 mg/kg daily). Outcomes were categorised as survival or death, with time-of-death intervals:  $\leq 2$  days, 3-7 days, 8-14 days, and 15-84 days. Kaplan-Meier analysis illustrated survival distribution, and a two-sample binomial test identified when mortality significantly declined.

Overall survival rate was 88%. For cats that survived the first seven days of treatment, survival rate increased to 97%. From 14 to 84 days of treatment, cats had a 98% survival rate. No difference in mortality rate was found when comparing effusive and non-effusive presentations.

In conclusion, use of remdesivir and/or GS-441524 in the effective treatment of FIP is well supported. Veterinarians may consider discussing the costs and mortality risks associated with the initial phase of treatment, followed by the full treatment costs and significantly improved survival rates beyond the first week. The enhanced survival rate after the initial treatment phase can provide owners with the reassurance needed to continue treatment.

### **Reference List**

1. Tasker S, Addie DD, Egberink H, Hofmann-Lehmann R, Hosie MJ, Truyen U, et al. Feline Infectious Peritonitis: European Advisory Board on Cat Diseases Guidelines. *Viruses*. 2023;15(9).
2. Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. *Journal of Feline Medicine and Surgery*. 2019;21(4):271-81.
3. Murphy BG, Perron M, Murakami E, Bauer K, Park Y, Eckstrand C, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. *Veterinary Microbiology*. 2018;219:226-33.